Efficacy and safety of corpus callosotomy versus vagus nerve stimulation as long-term adjunctive therapies in children with Lennox-Gastaut syndrome: Experience of a tertiary care center.
Journal
Neurosciences (Riyadh, Saudi Arabia)
ISSN: 1319-6138
Titre abrégé: Neurosciences (Riyadh)
Pays: Saudi Arabia
ID NLM: 101252453
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
24
10
2021
accepted:
11
01
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
30
4
2022
Statut:
ppublish
Résumé
To compare the efficacy and safety of corpus callosotomy versus vagus nerve stimulation (VNS) as long-term adjunctive therapies in children with Lennox-Gastaut syndrome. This retrospective study was conducted in King Fahad Medical City between 2010 and 2019. The authors identified and followed 9 patients with Lennox-Gastaut syndrome (LGS) who underwent corpus callosotomy or VNS implantation for at least 12 months; seizure frequency and major complications were monitored. Five patients with a mean age of 10.8±1.3 years had corpus callosotomy, and 4 patients with a mean age of 13.8±3.9 years were implanted with VNS stimulators. Reduction in seizure frequency was achieved in all 5 patients who underwent corpus callosotomy, with greater than 75% seizure reduction in more than 50% in one, and greater than 25% in 2 respectively. However, in those implanted with VNS, 2 (50%) patients achieved a reduction in seizure frequency of greater than 75% and 2 (50%) greater than 25%, respectively. No significant difference was observed between the 2 treatment groups. One patient who underwent corpus callosotomy suffered cerebrospinal fluid leakage, and swallowing difficulties in one patient who underwent VNS. Both corpus callosotomy and VNS are safe and effective as adjunctive treatments for LGS patients.
Identifiants
pubmed: 35477916
pii: 27/2/59
doi: 10.17712/nsj.2022.2.20210135
pmc: PMC9257907
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-64Informations de copyright
Copyright: © Neurosciences.
Références
Epilepsia. 1997 Dec;38(12):1283-8
pubmed: 9578523
J Clin Neurophysiol. 2003 Nov-Dec;20(6):426-41
pubmed: 14734932
Pediatrics. 1950 Apr;5(4):626-44
pubmed: 15417264
J Clin Neurophysiol. 2001 Sep;18(5):419-28
pubmed: 11709647
Acta Neurochir (Wien). 2016 May;158(5):1005-12
pubmed: 26979179
J Child Neurol. 2000 Aug;15(8):509-12
pubmed: 10961788
Seizure. 2012 Dec;21(10):760-3
pubmed: 22921514
Epilepsia. 1990;31 Suppl 2:S40-3
pubmed: 2121469
Epilepsy Behav. 2008 Aug;13(2):271-8
pubmed: 18539083
Epilepsia. 2001 Sep;42(9):1148-52
pubmed: 11580762
J Neurosci. 2020 Jul 15;40(29):5589-5603
pubmed: 32541070
Epilepsia. 2014 Sep;55 Suppl 4:4-9
pubmed: 25284032
Brain Dev. 2008 Mar;30(3):195-9
pubmed: 17825516
CNS Drugs. 2018 Oct;32(10):905-916
pubmed: 30132269
Recenti Prog Med. 1968 Aug;45(2):117-46
pubmed: 4984443
Pediatr Neurol. 2012 Sep;47(3):153-61
pubmed: 22883278
Epilepsia. 1997 May;38(5):526-31
pubmed: 9184597
Epilepsia. 2011 Aug;52 Suppl 5:3-9
pubmed: 21790560
Front Neurol. 2014 Oct 30;5:225
pubmed: 25400619
Epilepsy Res Treat. 2012;2012:403592
pubmed: 23213494
Seizure. 2013 Jan;22(1):3-8
pubmed: 23068970
Neurology. 2013 Oct 15;81(16):1453-9
pubmed: 23986299
Seizure. 2013 Jun;22(5):396-400
pubmed: 23490456
Epilepsy Behav. 2015 Oct;51:13-7
pubmed: 26247311
Epilepsia. 2001 Jan;42(1):67-71
pubmed: 11207787